Kessler Topaz Meltzer & Check, LLP Reminds Investors of June 6, 2022 Deadline in Securities Fraud Class Action against AbbVie, Inc. and Urges Investors with Substantial Losses to Contact the Firm
CLICK HERE TO SUBMIT YOUR ABBVIE (ABBV) LOSSES. YOU CAN ALSO CLICK ON THE FOLLOWING LINK OR COPY AND PASTE IN YOUR BROWSER: https://www.ktmc.com/new-cases/abbvie-inc?utm_source=PR&utm_medium=link&utm_campaign=abbvie&mktm=r
CANNOT VIEW THIS VIDEO? PLEASE CLICK HERE
TO VIEW OUR COMPLAINT, PLEASE CLICK HERE
LEAD PLAINTIFF DEADLINE:
CLASS PERIOD:
CONTACT AN ATTORNEY TO DISCUSS YOUR RIGHTS:
Kessler Topaz is one of the world’s foremost advocates in protecting the public against corporate fraud and other wrongdoing. Our securities fraud litigators are regularly recognized as leaders in the field individually and our firm is both feared and respected among the defense bar and the insurance bar. We are proud to have recovered billions of dollars for our clients and the classes of shareholders we represent.
ABBVIE’S ALLEGED MISCONDUCT
AbbVie (ABBV) is one of the world’s largest pharmaceutical companies. The company’s revenues will come under significant pressure in the coming years when its best-selling drug, Humira, will lose patent protection in 2023. Accordingly, AbbVie’s future revenue and earnings depend in large part on its ability to develop new sources of revenue to offset Humira’s lost sales. Rinvoq—an anti-inflammatory drug manufactured by AbbVie (ABBV) and used to treat rheumatoid arthritis (RA) and other diseases by inhibiting Janus kinase (JAK) enzymes—was touted as one such drug. Rinvoq was initially approved in
As is relevant here, Rinvoq is similar to other JAK inhibitor drugs, including Xeljanz, manufactured by Pfizer Inc. When the FDA approved Xeljanz in 2012 for the treatment of RA, it required an additional safety trial to evaluate Xeljanz’s risk of triggering certain serious side effects. Beginning in
However, investors began to learn the truth about Rinvoq’s significant risks on
Then, on
After the Class Period, on
The complaint alleges that, throughout the Class Period, the Defendants made materially false and/or misleading statements, about the company’s business and operations. Specifically, Defendants misrepresented and/or failed to disclose that: (1) safety concerns about Xeljanz extended to Rinvoq and other JAK inhibitors; (2) as a result, it was likely that the FDA would require additional safety warnings for Rinvoq and would delay the approval of additional treatment indications for Rinvoq; and (3) therefore, Defendants’ statements about the company’s business, operations, and prospects lacked a reasonable basis, As a result of the Defendants’ wrongful acts and omissions, and the significant decline in the market value of AbbVie’s securities, AbbVie (ABBV) investors have suffered significant damages.
WHAT CAN I DO?
AbbVie (ABBV) investors may, no later than
CLICK HERE TO SIGN UP FOR THE CASE
WHO CAN BE A LEAD PLAINTIFF?
A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.
ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP
Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country and around the world. The firm has developed a global reputation for excellence and has recovered billions of dollars for victims of fraud and other corporate misconduct. All of our work is driven by a common goal: to protect investors, consumers, employees and others from fraud, abuse, misconduct and negligence by businesses and fiduciaries. For more information about Kessler Topaz Meltzer & Check, LLP please visit www.ktmc.com.
CONTACT:
Kessler Topaz Meltzer & Check, LLP
280 King of
(484) 270-1453
info@ktmc.com
A video accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/88b0bbe1-8cc5-4458-a9d6-f023c204e770
Image: https://www.globenewswire.com/newsroom/ti?nf=ODU0NzA5OCM0OTI5NDU4IzIwMTkzMTI=Image: https://ml.globenewswire.com/media/Y2M3YmQ1YTYtOWUwMy00NTYxLTliMzAtMGQzMTY3NDMyNGRhLTEwMzA4ODU=/tiny/Kessler-Topaz-Meltzer-Check-LL.png
Image: Primary Logo
Source: Kessler Topaz Meltzer & Check LLP